These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Personalized neoantigen vaccines: A new approach to cancer immunotherapy. Aldous AR; Dong JZ Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369 [TBL] [Abstract][Full Text] [Related]
3. Endogenous CD4 Veatch JR; Jesernig BL; Kargl J; Fitzgibbon M; Lee SM; Baik C; Martins R; Houghton AM; Riddell SR Cancer Immunol Res; 2019 Jun; 7(6):910-922. PubMed ID: 31043415 [TBL] [Abstract][Full Text] [Related]
4. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255 [TBL] [Abstract][Full Text] [Related]
5. The present status and future prospects of peptide-based cancer vaccines. Hirayama M; Nishimura Y Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694 [TBL] [Abstract][Full Text] [Related]
6. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. Lu YC; Zheng Z; Robbins PF; Tran E; Prickett TD; Gartner JJ; Li YF; Ray S; Franco Z; Bliskovsky V; Fitzgerald PC; Rosenberg SA Mol Ther; 2018 Feb; 26(2):379-389. PubMed ID: 29174843 [TBL] [Abstract][Full Text] [Related]
7. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371 [TBL] [Abstract][Full Text] [Related]
8. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model. Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785 [TBL] [Abstract][Full Text] [Related]
9. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Haabeth OAW; Blake TR; McKinlay CJ; Waymouth RM; Wender PA; Levy R Proc Natl Acad Sci U S A; 2018 Sep; 115(39):E9153-E9161. PubMed ID: 30201728 [TBL] [Abstract][Full Text] [Related]
10. mRNA Cancer Vaccines. Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688 [TBL] [Abstract][Full Text] [Related]